Increased high-sensitivity c-reactive protein predicts a high risk of lower urinary tract symptoms in chinese male: Results from the fangchenggang area male health and examination survey

Prostate

Volumn 72, Issue 2, 2012, Pages 193-200

  Lu, Zheng ^a   Gao, Yong ^b   Tan, Aihua ^b   Yang, Xiaobo ^b   Zhang, Haiying ^b   Mo, Linjian ^a   Wu, Chunlei ^b   Hu, Yanling ^b   Mo, Zengnan ^a,b  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

benign prostatic hyperplasia; cross sectional; inflammation

Indexed keywords

C REACTIVE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CHINA; CONTROLLED STUDY; DIABETES MELLITUS; DRINKING BEHAVIOR; DYSLIPIDEMIA; HEALTH SURVEY; HUMAN; HYPERTENSION; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOCTURIA; PHYSICAL ACTIVITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; URINARY URGENCY; WAIST HIP RATIO;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; HUMANS; LOGISTIC MODELS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; QUESTIONNAIRES; YOUNG ADULT;

EID: 84455199895     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21421     Document Type: Article

References (35)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A,. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61 (1): 37-49. (Pubitemid 36151708)
2. Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, Seo JT, Lee JG, Park HS, Choo MS,. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: Results of Korean EPIC study. World J Urol 2011; 29 (2): 185-190.
3. Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, Link CL, McKinlay JB,. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: The Boston Area Community Health (BACH) Survey. Arch Intern Med 2006; 166 (21): 2381-2387. (Pubitemid 44833365)
4. Haidinger G, Madersbacher S, Waldhoer T, Lunglmayr G, Vutuc C,. The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables. Eur J Epidemiol 1999; 15 (8): 717-722. (Pubitemid 29493111)
5. Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP,. The burden of lower urinary tract symptoms: Evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 2009; 103 (Suppl. 3): 4-11.
6. Quek KF,. Factors affecting health-related quality of life among patients with lower urinary tract symptoms. Int J Urol 2005; 12 (12): 1032-1036. (Pubitemid 43110213)
7. Wei JT, Calhoun E, Jacobsen SJ,. Urologic diseases in america project: Benign prostatic hyperplasia. J Urol 2008; 179 (5 Suppl): S75-S80. (Pubitemid 351483917)
8. Nickel JC, Downey J, Young I, Boag S,. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84 (9): 976-981.
9. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A,. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol 2003; 43 (2): 164-175. (Pubitemid 36221971)
10. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA,. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005; 62 (1): 27-33. (Pubitemid 39614290)
11. Kupelian V, McVary KT, Barry MJ, Link CL, Rosen RC, Aiyer LP, Mollon P, McKinlay JB,. Association of C-reactive protein and lower urinary tract symptoms in men and women: Results from Boston Area Community Health survey. Urology 2009; 73 (5): 950-957.
12. St Sauver JL, Sarma AV, Jacobson DJ, McGree ME, Lieber MM, Girman CJ, Nehra A, Jacobsen SJ,. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 2009; 169 (11): 1281-1290.
13. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH, Jr, Grundy SM, de Lemos JA,. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005; 46 (3): 464-469. (Pubitemid 41040287)
14. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, Lonn E, Teo K, McQueen M, Yusuf S,. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004; 24 (8): 1509-1515. (Pubitemid 39050449)
15. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, James SA, Cooney KA, Doerr KM, Montie JE, Schottenfeld D,. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003; 157 (10): 906-914. (Pubitemid 36555050)
16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 1): S5-S20.
17. Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 2007; 35 (5): 390-419.
18. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP, Wein AJ,. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: Results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104 (3): 352-360.
19. Chen C, Lu FC,. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci 2004; 17 Suppl: 1-36.
20. Kessler OJ, Keisari Y, Servadio C, Abramovici A,. Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol 1998; 159 (3): 1049-1053. (Pubitemid 28106592)
21. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ,. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56 (3): 171-182. (Pubitemid 36918167)
22. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M,. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52 (1): 43-58. (Pubitemid 34553191)
23. Yamaguchi O, Aikawa K, Shishido K, Nomiya M,. Place of overactive bladder in male lower urinary tract symptoms. World J Urol 2009; 27 (6): 723-728.
24. Roosen A, Chapple CR, Dmochowski RR, Fowler CJ, Gratzke C, Roehrborn CG, Stief CG, Andersson KE,. A refocus on the bladder as the originator of storage lower urinary tract symptoms: A systematic review of the latest literature. Eur Urol 2009; 56 (5): 810-819.
25. Yoshimura N,. Lower urinary tract symptoms (LUTS) and bladder afferent activity. Neurourol Urodyn 2007; 26 (6 Suppl.): 908-913. (Pubitemid 47548227)
26. Maggi CA, Evangelista S, Grimaldi G, Santicioli P, Giolitti A, Meli A,. Evidence for the involvement of arachidonic acid metabolites in spontaneous and drug-induced contractions of rat urinary bladder. J Pharmacol Exp Ther 1984; 230 (2): 500-513. (Pubitemid 14061635)
27. Palea S, Toson G, Pietra C, Trist DG, Artibani W, Romano O, Corsi M,. Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder. Br J Pharmacol 1998; 124 (5): 865-872. (Pubitemid 28312819)
28. Fusco F, Groutz A, Blaivas JG, Chaikin DC, Weiss JP,. Videourodynamic studies in men with lower urinary tract symptoms: A comparison of community based versus referral urological practices. J Urol 2001; 166 (3): 910-913. (Pubitemid 32750980)
29. Berry SJ, Coffey DS, Walsh PC, Ewing LL,. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132 (3): 474-479. (Pubitemid 14026148)
30. Saltevo J, Vanhala M, Kautiainen H, Kumpusalo E, Laakso M,. Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome. Mediators Inflamm 2007; 2007: 93573.
31. Schillaci G, Pirro M,. C-reactive protein in hypertension: Clinical significance and predictive value. Nutr Metab Cardiovasc Dis 2006; 16 (7): 500-55508.
32. Wee CC, Mukamal KJ, Huang A, Davis RB, McCarthy EP, Mittleman MA,. Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) 2008; 16 (4): 875-880. (Pubitemid 351465646)
33. Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, Shin Y, Paik HY, Lee C,. A high-risk group for prostatism: A population-based epidemiological study in Korea. Br J Urol 1997; 79 (5): 736-741. (Pubitemid 28312593)
34. Dehghan A, van Hoek M, Sijbrands EJ, Stijnen T, Hofman A, Witteman JC,. Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care 2007; 30 (10): 2695-2699. (Pubitemid 47547822)
35. Haidinger G, Temml C, Schatzl G, Brossner C, Roehlich M, Schmidbauer CP, Madersbacher S,. Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology. Eur Urol 2000; 37 (4): 413-420.